CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 15 enrolled
Drug / intervention
Topical aminocaproic acid (ACA) mixed with Vanicream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01398280
NCT01398280Early Ph 1Completed
CompareCT.gov

A Single Site Evaluation of the Effect of Topical Application of Aminocaproic Acid (ACA) to Inhibit Kallikrein 5 Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation.

University of California, San Diego·interventional·Posted Jul 20, 2011·Updated Sep 13, 2019

In Brief

A Early Phase 1 clinical trial evaluating Topical aminocaproic acid (ACA) mixed with Vanicream and Vehicle cream for Rosacea. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effect of topical aminocaproic acid on the immune system by assessing the levels of antimicrobial peptides in the skin of patients with rosacea. It is hypothesized that aminocaproic acid applied topically will alter the body's immune system in patients with rosacea by inhibiting activation of antimicrobial peptides.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 20, 2011
Enrollment StartJul 1, 2011
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.0 years ago

Interventions

Topical aminocaproic acid (ACA) mixed with Vanicreamdrug

25% Aminocaproic acid cream twice daily for up to 12 weeks.

Vehicle creamdrug

Vehicle cream moisturizer twice daily for up to 12 weeks